PYXIS ONCOLOGY INC

Pyxis Oncology CEO’s option buy backs after a $50 m private placement, boosting confidence and potentially driving faster clinical progress and shareholder value.

Insider Dupont Jakob’s Rule 10b5‑1 trades show Pyxis Oncology’s disciplined strategy and growing confidence, hinting at future upside.

Insider buying at Pyxis Oncology shows executive confidence amid volatility, as Wadhane Jitendra purchases shares and options, signaling a bullish outlook and long‑term upside potential.

Pyxis Oncology insider buying spree shows executive confidence, but investors must watch upcoming clinical milestones, regulatory decisions, and dilution risks to gauge true upside potential.

Executives buy 45,867 zero‑cost options each, signaling bullish confidence amid a near‑neutral market and 457% social‑media buzz—watch next year’s vesting for a potential price lift.

Insider sales at Pyxis Oncology reveal a cautious liquidity move amid a volatile market. Evaluate the company’s dilution risk, pipeline uncertainty, and long‑term upside before investing.

Pyxis Oncology’s CEO buys 690k shares at $0.00, a sign of confidence as the company targets ADC breakthroughs, regulatory milestones, and potential upside for investors.